Thomsen-Friedenreich antigen antigens

Therapeutic vaccines were tested in BALB/c mice bearing TA3-Ha mammary carcinoma. The treatment consisted of 4 subcutaneous injections, at 3-6 days intervals, of Detox [a commercial preparation of cell wall skeletons from Mycobacterium phlei and non-toxic monophosphoryl lipid A from Salmonella minnesota (S. minnesota) in squalane oil and Tween 80 from Ribi Immunochemical research, Montana, USA] mixed with Thomsen-Friedenreich (TF) antigen coupled with KLH (Keyhole Limpet Hemocyanin) performed 5 days after the tumor cell injection. This vaccination achieved the survival of 25 % of the mice. Pretreatment of mice with cyclophosphamide in order to inhibit any suppressive response, increased survival to 50 % when the treatment began 5 days after tumor cell injection, and to 90 % when the treatment began 2 days after tumor cell injection. Both antibody as well as delayed-... 

Because O-glycosylation can also be accomplished with active esters (e.g., penta-fluorophenyl esters) [11] of Fmoc serine and threonine, the Fmoc technique provides a general method for the synthesis of glycopeptides. Thomsen-Friedenreich antigen glycopeptides and neoglycoproteins have been obtained by this method in preparative amounts [12], In combination with acid-labile polymeric benzyl ester anchors, this Fmoc technique was applied to solid-phase syntheses of glycopeptides [11,13,14]. 

Use of a Synthetic Hapten in the Demonstration of the Thomsen Friedenreich (T) Antigen on Neuraminidase-Treated Human Red Blood Cells and Lymphocytes, J. Bray, R. U. Lemieux, and T. A. McPherson, J. Immunol., 126 (1981) 1966-1969. 

L. Kroger, A. Scudlo, and J. Thiem, Subsequent enzymatic galactosylation and sialylation towards sialylated Thomsen-Friedenreich antigen components, Adv. Synth. Catal., 348 (2006) 1217—1227. 

All cells are covered by a thick layer of carbohydrates, known as the glycocalyx, which consists of many different carbohydrate epitopes. The unique or overexpressed carbohydrate structures on cancer cells are termed TACAs. The Thomsen-Friedenreich (TF) antigen was the first TACA identified with the help of a specific monoclonal antibody (mAh) and mass spectrometry. Since then, a number of TACAs have been characterized. Figure 1 shows some of the representative TACAs. 

Campbell BJ, Finnie lA, Hounsell EF et al. (1995) Direct demonstration of increased expression of Thomsen-Friedenreich (TF) antigen from colonic adenocarcinoma and ulcerative colitis mucin and its concealment in normal mucin. J Clin Invest 95 571-576. 

The T antigenic structure (the Thomsen-Friedenreich or TF antigen) is derived from the precursor Tn antigen [90]. The disaccharide is also a-O-linked to serine or threonine in the peptide backbone (O Fig. 4). 

PAM AMs [poly(amidoamine) dendrimers] are commercially available hyperbranched cores. T-antigen [Thomsen-Friedenreich, [3-Gal-(l,3)-oc-D-GalNAc-OR, 29] was successfully attached to PAMAM 30 via a 3-(propyl)mercaptopropionic acid linker to investigate T-antigen-protein interactions [44] (Scheme 20.8). 

S. A. Svarovsky, Z. Szekely, and J. J. Barchi, Synthesis of gold nanoparticles bearing the Thomsen-Friedenreich disaccharide A new multivalent presentation of an important tumor antigen, Tetrahedron Asymmetry, 16 (2005) 587-598. 

C14H25NO11 383.352 Isol. from the acid hydrolysate of human blood group A, B, H and Le substances. TF-antigenic disaccharide (Thomsen-Friedenreich). Mg +34.5 (c, 0.3 in H2O). 

---